Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells. Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.

<p>Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells.</p>
<p>Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.</p>


Poseida Therapeutics

Roche inks $1.5B Poseida buyout, betting off-the-shelf CAR-Ts will democratize access to cell therapies - Fierce Biotech

 Roche: completes acquisition of Poseida Therapeutics 

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - PR Newswire

                                    Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells
                                

 $TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of PFIE, PSTX, ARCH, B to Take Action 

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - Yahoo Finance

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

 In Vitro Diagnostics Market worth US$157,632.5 million by 2030 with 7.6% CAGR | MarketsandMarkets™ 

 Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P TMI Index 

Join us at our November A2I Coffee Club on November 21 from 6:30pm-7:30pm on Zoom! This time we will focus on the Science and Scope of CAR T-cell Therapy with two specialists from Poseida Therapeutics! Register at https://lnkd.in/gnyfbSpU or by scanning QR code on flyer. Visit AWIS.org for membership details and email A2i@AWISSD.org for more meeting info.

 POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX 

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion - The Wall Street Journal

Poseida Therapeutics (NASDAQ:PSTX) Hits New 12-Month High - Here's Why - MarketBeat

Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 bln deal - Reuters

 Auto stocks lead losses in Europe on Trump’s tariff risk 

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer - PR Newswire

 Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting 

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B - Yahoo Finance


                        
                            
                                Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
                                
                                    
                                        
                                        Press Release
                                     | 
                                    November 14, 2024
                                
                            
                        
                    

PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors - Barron's

Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition - BioProcess International

Poseida Therapeutics guns again for IPO


                        
                            
                                P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma
                                
                                    
                                                                                    OncLive
                                                                             | 
                                    September 30, 2024
                                
                            
                        
                    

 SDBJ Insider 


                        
                            
                                CAR-T and Related Therapies Home In on Autoimmune Disease
                                
                                    
                                                                                    BioSpace
                                                                             | 
                                    November 4, 2024
                                
                            
                        
                    

Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion - BioPharma-Reporter.com

 Cantor Fitzgerald Downgrades Poseida Therapeutics, Inc (PSTX) to Neutral 

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

 Auto stocks lead losses in Europe on Trump's tariff risk 

 Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies 

 Roche to buy cell therapy developer Poseida for $1B 

Poseida Therapeutics to Present at Two Upcoming Investor Conferences - PR Newswire


                        
                            
                                The Allogeneic Future with Poseida’s Kristin Yarema, Ph.D.
                                
                                    
                                                                                    Bioprocess Online
                                                                             | 
                                    August 5, 2024
                                
                            
                        
                    

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire

Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 - PR Newswire


                        
                            
                                Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
                                
                                    
                                                                                    CGTLive
                                                                             | 
                                    November 17, 2024
                                
                            
                        
                    

 European stocks echo global market downturn on tariff risk; auto shares slump 

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Roche to buy cell therapy developer Poseida for $1B - BioPharma Dive

 Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting 

Roche Completes Major Acquisition of Poseida Therapeutics with 66% Share Tender Success - Stock Titan

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies - Roche

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance

Why This Gene-Therapy Company’s Stock Is Rising 228% - Barron's

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

 Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show 

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PR Newswire

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of Shareholders 

Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida - Reuters

 European stocks mostly lower; German economic data disappoints 

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PR Newswire

Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan

We’re thrilled to announce Poseida entered into a definitive agreement to be acquired by Roche Holdings, Inc. At the closing of the proposed transaction, Poseida and its employees will join the Roche Group and advance our innovative pipeline of non-viral, Tscm-rich CAR-T therapies and genetic medicines as part of Roche’s Pharmaceuticals Division. Details here: https://lnkd.in/gvbwFU7r

#CapacitytoCure #celltherapy #CART #geneticmedicines

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - MedCity News

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma - PR Newswire

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - BioSpace

 Key Market Driver In B Cell Maturation Antigen BCMA Targeted Therapies Industry 2025: Rising Incidence Of Multiple 

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - PR Newswire

Roche to acquire Poseida Therapeutics for $1.5bn - Pharmaceutical Technology

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders 

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PR Newswire



  Company Logo             to go to home page    	 	 		 		 		 		 		 		 	 	 		 		 		 			 			 			 			 			 			 			 			 			 			 			 		 		 			 			 		 		 			 			 		 	  


 Level Access Solution for people at Poseida Therapeutics 

  

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know - Yahoo Finance

 Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen 

 Roche commences tender offer for outstanding Poseida shares at $9 per share 

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting


                        
                            
                                Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
                                
                                    
                                        
                                        Press Release
                                     | 
                                    November 26, 2024
                                
                            
                        
                    

 Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029 

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - Yahoo Finance

#CellandGeneTherapies are transforming our approach to treating disease, offering more precise disease-modifying and, in some cases, potentially curative solutions that give new hope to patients. This potential was evident when I attended #CGMesa24 recently, where scientific progress in the field took the spotlight and stories highlighting the impact on patients served as a powerful reminder of why our efforts matter and the power innovation holds to change lives.
 
I was delighted to join a fireside chat with Kristin Yarema, Ph.D., President and CEO of Poseida Therapeutics – one of our key innovation partners in cell therapy – to discuss the advances Astellas is making in cell and gene therapy. 
 
In addition, my colleagues Richard Wilson, Primary Focus Lead, Genetic Regulation, and Ha Tran, MD, MS, Head of Medical Development, Cell and Gene Therapy, shared their expertise during the meeting, addressing critical challenges and opportunities in the field alongside updates on our work in cell and gene therapy. 
 
A few key insights from the event that resonated with me: 
New approvals are rapidly advancing. We’ve seen a number of high profile approvals in areas such as advanced synovial sarcoma and Hemophilia B, and up to 14 cell and gene therapy approvals are expected this year across the US and EU – signaling positive momentum toward the FDA’s goal of 10 to 20 approvals per year starting in 2025.
After seeing somewhat of a slowdown in 2022 and 2023, investment in cell and gene therapy is resurging. Strong clinical data and positive real-world evidence are supporting investor confidence, particularly in late-stage assets, setting the stage for further innovation and growth.
Manufacturing remains a significant challenge to ensuring these innovative therapies reach patients in need. Manufacturing methods vary depending on the type of therapy and cell source, with differing levels of complexity. Navigating this complexity requires substantial and early investment to standardize protocols and build the infrastructure needed to enable scaling up. 
 
Taken together, these insights highlight the significant progress we’re making, but they also underscore the work ahead. I’m proud to be leading a team at Astellas Pharma who shares this commitment to bringing transformative therapies to patients in need. 
 
#ScienceFirstForPatients #ChangingTomorrow 

 Roche to Stay ‘Disciplined’ With Deals in 2025 

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - GlobeNewswire

Roche purchases shares in tender offer for Poseida Therapeutics, Inc. - GlobeNewswire

Roche inks $1.5B Poseida buyout to land off-the-shelf CAR ...

Roche's $1.5B Poseida Therapeutics Acquisition | Transforming - openPR.com


              Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
            

 Oncology Biosimilars Market Size to Reach USD 35.79 Billion By 2034 

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Yahoo Finance

 Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion 

Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show - Endpoints News

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

 NTT DATA's Acquisition of Niveus Solutions to Strengthen Google Cloud Capabilities 

Poseida Therapeutics stock hits 52-week high at $9.28 - Investing.com

Big Pharma, big CGT deals: Roche buying Poseida, Novartis buys Kate - BioProcess International

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

Why Poseida Therapeutics Stock Is Rising 228% - Barron's

Poseida stock jumps on $1.5B Roche buyout (NASDAQ:PSTX) - Seeking Alpha

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - PR Newswire

UPDATE: After FDA's CAR-T concerns, Poseida's Roche ...

We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24!

https://lnkd.in/e-S-tFeJ

#CapacitytoCure #celltherapy

 Roche to close $1.5B acquisition of Poseida Therapeutics 

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, ZUO, PSTX on Behalf of Shareholders 

Roche enters into a definitive agreement to acquire Poseida - GlobeNewswire

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma - PR Newswire

Roche to acquire Poseida Therapeutics for $1.5bn - Yahoo Finance

Roche Acquires Poseida for $1.5B - San Diego Business Journal

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma - PR Newswire


                        
                            
                                Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
                                
                                    
                                                                                    AJMC
                                                                             | 
                                    October 2, 2024
                                
                            
                        
                    

Poseida Therapeutics

Business:

Drug notes:

About: